Selexis SA CEO to Speak at the BioProcess Theater at BIO 2014

Dr. Igor Fisch to Present Data on Using Genome Engineering and the Selexis SURE CHO-Mplus Libraries for Optimal Transgene Expression and Recombinant Protein Production

| Source: Selexis SA

GENEVA, Switzerland, May 30, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development announced today the Company's CEO, Igor Fisch, Ph.D., will present "Genome Engineering and SURE CHO-Mplus Libraries™ for Optimal Transgene Expression and Recombinant Protein Production" at the BioProcess Theater on June 24, 2014 at 2:30 PM. The BioProcess Theater presentations are part of the BIO International Convention being held Jun 23-26 in San Diego, California at the San Diego Convention Center.

Presentation Abstract:

Based on proprietary epigenetic DNA regulator elements and leveraging the SURE CHO-M Genome and Transcriptome, Selexis has developed a novel platform approach for the generation of CHO cell lines. By combining robust transcription with a library approach to debottlenecking translation, folding and secretion, Selexis has launched the SURE CHOM-Mplus™ Libraries. This technology has an extensive history of generating high-level, stable expressing cell lines, including cell lines producing difficult-to-express proteins such as Fc-fusions and large multimeric proteins. The extensive characterization of the CHO-M cell line supports comprehensive and effective transfer packages for manufacturing.

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit

Selexis SA
Robert Meister